These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33987408)

  • 41. Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma.
    Dai W; Ko JMY; Choi SSA; Yu Z; Ning L; Zheng H; Gopalan V; Chan KT; Lee NP; Chan KW; Law SY; Lam AK; Lung ML
    J Pathol; 2017 Aug; 242(4):500-510. PubMed ID: 28608921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
    Zhang LL; Kan M; Zhang MM; Yu SS; Xie HJ; Gu ZH; Wang HN; Zhao SX; Zhou GB; Song HD; Zheng CX
    Int J Cancer; 2017 Jan; 140(1):103-108. PubMed ID: 27646734
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.
    Erickson BK; Kinde I; Dobbin ZC; Wang Y; Martin JY; Alvarez RD; Conner MG; Huh WK; Roden RBS; Kinzler KW; Papadopoulos N; Vogelstein B; Diaz LA; Landen CN
    Obstet Gynecol; 2014 Nov; 124(5):881-885. PubMed ID: 25437714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. miR-7 expression in serous ovarian carcinomas.
    Swiercz A; Chechlinska M; Kupryjanczyk J; Dansonka-Mieszkowska A; Rembiszewska A; Goryca K; Kulinczak M; Zajdel M; Sromek M; Siwicki JK
    Anticancer Res; 2015 Apr; 35(4):2423-9. PubMed ID: 25862909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.
    Mullany LK; Wong KK; Marciano DC; Katsonis P; King-Crane ER; Ren YA; Lichtarge O; Richards JS
    Neoplasia; 2015 Oct; 17(10):789-803. PubMed ID: 26585234
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.
    Kim YM; Lee SW; Chun SM; Kim DY; Kim JH; Kim KR; Kim YT; Nam JH; van Hummelen P; MacConaill LE; Hahn WC; Jang SJ
    PLoS One; 2014; 9(6):e99451. PubMed ID: 24936796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
    Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer.
    Park YR; Kim YM; Lee SW; Lee HY; Lee GE; Lee JE; Kim YT
    Obstet Gynecol Sci; 2018 May; 61(3):328-336. PubMed ID: 29780774
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
    Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
    J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Wang W; Liu R; Liao W; Ji L; Mei J; Su D
    Aging (Albany NY); 2023 Sep; 15(18):9743-9758. PubMed ID: 37728427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy.
    Saleh A; Perets R
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
    Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
    Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Vitale SR; Groenendijk FH; van Marion R; Beaufort CM; Helmijr JC; Dubbink HJ; Dinjens WNM; Ewing-Graham PC; Smolders R; van Doorn HC; Boere IA; Berns EMJJ; Helleman J; Jansen MPHM
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32156073
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
    Tworek H; Peng R; Fetzer S; Werness BA; Piver MS; Allen HJ; DiCioccio RA
    Cancer Genet Cytogenet; 1999 Jul; 112(2):105-18. PubMed ID: 10686936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection.
    Shimizu T; Marusawa H; Matsumoto Y; Inuzuka T; Ikeda A; Fujii Y; Minamiguchi S; Miyamoto S; Kou T; Sakai Y; Crabtree JE; Chiba T
    Gastroenterology; 2014 Aug; 147(2):407-17.e3. PubMed ID: 24786892
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
    Werness BA; Parvatiyar P; Ramus SJ; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; DiCioccio RA; Wiest J; Tsukada Y; Ponder BA; Piver MS
    J Natl Cancer Inst; 2000 Jul; 92(13):1088-91. PubMed ID: 10880552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis.
    Wen WH; Bernstein L; Lescallett J; Beazer-Barclay Y; Sullivan-Halley J; White M; Press MF
    Cancer Res; 2000 May; 60(10):2716-22. PubMed ID: 10825146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The consequence of oncomorphic TP53 mutations in ovarian cancer.
    Brachova P; Thiel KW; Leslie KK
    Int J Mol Sci; 2013 Sep; 14(9):19257-75. PubMed ID: 24065105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.